A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Status:
Recruiting
Trial end date:
2022-07-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of oral administration of
itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female
participants aged 12 years or older and who are planning to receive an approved immune
effector cell (IEC) therapy for hematologic malignancies.